The U.S. Food and Drug Administration announced Friday that it will postpone an advisory panel meeting that was slated for next week to weigh Pfizer’s COVID vaccine for use in young children.
The FDA took the step after Pfizer notified the agency that it would like to wait until data is available on a three-dose regimen for children aged 6 months to 4 years old, Pfizer said in a statement.
